ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time

This study is currently recruiting participants.
Verified by Queen's University, October 2008

Sponsored by: Queen's University
Information provided by: Queen's University
ClinicalTrials.gov Identifier: NCT00537472
  Purpose

This study plans to investigate whether a reduced dose of bupivacaine (a local anesthetic numbing drug) injected into the spinal space for a total knee replacement will result in a shorter time to discharge from the recovery room while maintaining adequate surgical anesthesia.


Condition Intervention
Spinal Anesthesia
Total Knee Arthroplasty
Drug: Low dose bupivicaine in spinal anesthetic
Drug: Standard dose bupivacaine in spinal anesthetic

MedlinePlus related topics:   Anesthesia    Knee Replacement   

Drug Information available for:   Bupivacaine    Bupivacaine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:   Low Dose Spinal Bupivacaine for Total Knee Arthroplasty and Recovery Room Wait Time

Further study details as provided by Queen's University:

Primary Outcome Measures:
  • Time from spinal injection of bupivicaine until recovery room discharge criteria met. [ Time Frame: Until recovery room discharge post surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Need for pharmacologic rescue from inadequate spinal block during the procedure. [ Time Frame: Until end of surgery ] [ Designated as safety issue: Yes ]
  • Time from entrance into recovery room until criteria for a recovery room discharge are met [ Time Frame: Until recovery room discharge criteria are met ] [ Designated as safety issue: No ]
  • Time from entrance into recovery room until criteria for a femoral nerve block for post-operative pain control are met [ Time Frame: Until criteria are met for post operative nerve block in recovery room ] [ Designated as safety issue: No ]

Estimated Enrollment:   140
Study Start Date:   October 2007
Estimated Study Completion Date:   April 2009
Estimated Primary Completion Date:   April 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
I: Experimental Drug: Low dose bupivicaine in spinal anesthetic
Bupivacaine 9 mg intrathecal single shot injection at start of surgery
II: Active Comparator Drug: Standard dose bupivacaine in spinal anesthetic
Bupivacaine 13 mg intrathecal single shot injection at start of surgery

Detailed Description:

With the doses of bupivacaine currently being used in spinal anesthetics at our institution, patients' sensory blocks are often much higher than needed to achieve adequate surgical anesthesia. This translates into a prolonged waiting period in the recovery room before the level regresses down to the pre-existing standard for discharge to the ward, as well as the pre-existing level before a post-operative nerve block for extended pain relief can be performed. This prolonged period in the recovery room leads to general delays in operating room usage and thus surgical cancellations. The excessive drug doses currently used also put patients at risk for increasing side effects including low blood pressure, slow heart rates, and nausea and vomiting.

By using a reduced dose of bupivacaine in a spinal anesthetic for a one sided knee replacement, we hope to significantly reduce the recovery room waiting times until the criteria for recovery room discharge or completion of a post-operative nerve block are met, while still providing adequate surgical anesthesia.

Patients will receive either 9 mg (intervention dose) or 13 mg (control dose) of bupivacaine through a spinal injection. Once the patients enter the recovery room after surgery the level of their sensory block will be tested as per usual protocol by the recovery room nurses every 15 minutes until a predefined level has been reached, and the two groups will be compared.

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients undergoing elective one-sided total knee replacement for osteoarthritis at our institution where spinal anesthesia has been chosen by the patient and the anesthetist

Exclusion Criteria:

  • Contraindications to spinal anesthesia (such as increase pressure in brain, bleeding disorder, serious valvular heart disease, serious infection in the blood or on your lower back, certain neurological disorders such as multiple sclerosis, desire for a general anesthetic)
  • Allergies to local anesthetics, morphine or fentanyl
  • Both knees being done at same surgery
  • Revision of a previous knee replacement
  • Knee replacement for reasons other than osteoarthritis (such as rheumatoid arthritis)
  • Potential for difficult intubation in case of need for general anesthetic
  • Patients under 150 cm or over 200 cm
  • BMI greater than 40
  • Lack of patient consent or patient refusal
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00537472

Contacts
Contact: Devin Sydor, MD     613-548-7827     devsyd@gmail.com    
Contact: Melanie Jaeger, MD, FRCPSC     613-548-7827     jaegerm@kgh.kari.net    

Locations
Canada, Ontario
Kingston General Hospital     Recruiting
      Kingston, Ontario, Canada, K7L 2V7
      Principal Investigator: Melanie Jaeger, MD, FRCPSC            
      Sub-Investigator: Dale Engen, MD, FRCPSC            
      Sub-Investigator: Devin Sydor, MD            

Sponsors and Collaborators
Queen's University

Investigators
Principal Investigator:     Melanie Jaeger, MD, FRCPSC     Staff anesthesiologist at Kingston General Hospital    
Study Director:     Dale Engen, MD, FRCPSC     Staff anesthesiologist at Kingston General Hospital    
Study Director:     Devin Sydor, MD     Anesthesiology resident at Kingston General Hospital/Queen's University    
  More Information


Responsible Party:   Queens University and Kingston General Hospital ( Melanie Jaeger, MD, FRCPC )
Study ID Numbers:   6106
First Received:   September 28, 2007
Last Updated:   October 8, 2008
ClinicalTrials.gov Identifier:   NCT00537472
Health Authority:   Canada: Ethics Review Committee

Keywords provided by Queen's University:
Bupivacaine  
spinal anesthesia  
total knee arthroplasty  

Study placed in the following topic categories:
Bupivacaine

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions
Anesthetics, Local

ClinicalTrials.gov processed this record on October 24, 2008




Links to all studies - primarily for crawlers